Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitro

Abstract Background Malignant pleural mesothelioma (MPM) is a tumour arising from pleural cavities with poor prognosis. Multimodality treatment with pemetrexed combined with cisplatin shows unsatisfying response-rates of 40%. The reasons for the rather poor efficacy of chemotherapeutic treatment are...

全面介紹

書目詳細資料

發表在:	BMC Cancer
Main Authors:	Sabrina Borchert, Michael Wessolly, Jan Schmeller, Elena Mairinger, Jens Kollmeier, Thomas Hager, Thomas Mairinger, Thomas Herold, Daniel C. Christoph, Robert F. H. Walter, Wilfried E. E. Eberhardt, Till Plönes, Jeremias Wohlschlaeger, Clemens Aigner, Kurt Werner Schmid, Fabian D. Mairinger
格式:	Article
語言:	英语
出版:	BMC 2019-01-01
主題:	Malignant pleural mesothelioma - overall survival PARP1 BRCAness - BAP1 Olaparib
在線閱讀:	http://link.springer.com/article/10.1186/s12885-019-5314-0